Diagnostic Performance of Quantitative κ and λ Free Light Chain Assays in Clinical Practice
Top Cited Papers
Open Access
- 1 May 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (5) , 878-881
- https://doi.org/10.1373/clinchem.2004.046870
Abstract
Background: The quantitative assay for free light chains (FLCs) is a recently introduced commercial test reported to be sensitive and specific for detecting FLC diseases such as primary systemic amyloidosis (AL), light chain deposition disease (LCDD), nonsecretory multiple myeloma (NSMM), and light chain multiple myeloma. We evaluated its diagnostic performance in clinical practice.Keywords
This publication has 7 references indexed in Scilit:
- Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significanceBritish Journal of Haematology, 2004
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBritish Journal of Haematology, 2003
- Serum test for assessment of patients with Bence Jones myelomaThe Lancet, 2003
- Quantitative Analysis of Serum Free Light ChainsAmerican Journal of Clinical Pathology, 2003
- Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light ChainsClinical Chemistry, 2002
- Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myelomaBlood, 2001
- Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and UrineClinical Chemistry, 2001